

# Helvion Medical

Prepared for Tobias Lang · 13 October 2026 · Sample brief: names and figures are illustrative

## Strong Fit

### MATURITY: ESTABLISHED

Helvion Medical is an ideal customer for Brennwald Automation. They are a large, established medical technology company [S1] that manufactures high volumes of plastic components for self-injection devices in-house, including injection moulding and assembly [S2]. They operate over 140 injection moulding machines and use highly automated assembly processes for millions of units annually [S2]. Crucially, Helvion Medical is undergoing significant global manufacturing expansion, including new plants in the US [S4] and investments in digital manufacturing foundations [S3], commissioning new high-capacity lines [S5], and expanding tool manufacturing [S7]. This expansion is driven by strong demand and numerous new customer projects [S5], directly aligning with Brennwald Automation's offering of automation for plastics injection moulding, high-speed take-out systems, downstream assembly, inspection, packaging, and turnkey production lines for medical devices and high-volume disposables.

**Note:** Data gaps exist regarding Helvion Medical's current suppliers for automation and specific challenges they face, which could impact the sales cycle.

## CONTACT PROFILE

### Daniel Brunner

#### CHIEF OPERATING OFFICER AND DEPUTY CEO

Verified by Prospectr · source

#### BACKGROUND

Daniel Brunner has been the Chief Operating Officer (COO) since 2017 and Deputy CEO of Helvion Medical [S8]. He holds a B.S. in Mechanical Engineering and has prior experience in global operations and production management roles at other medical technology companies [S9].

#### SIGNALS

His mechanical engineering background and extensive experience in global operations and production management [S9] suggest he values technical efficiency, scalability, and robust manufacturing processes.

#### WHY THEY WILL CARE

As COO and Deputy CEO [S8], Daniel Brunner is directly responsible for ensuring Helvion Medical's manufacturing operations can meet the demands of rapid growth and new customer projects [S5]. Brennwald Automation's solutions can help him achieve efficient, high-volume production, integrate with digital manufacturing initiatives [S3], and ensure successful commissioning of new lines and plants [S4].

#### OPENING HOOK

*Given Helvion Medical's significant global manufacturing expansion, including the new US facility [S4] and the digital foundation at Leipzig II [S3], I wanted to connect regarding how Brennwald Automation's high-speed injection moulding and assembly lines could support your ambitious production scale-up for autoinjectors.*

## ABOUT THIS COMPANY

### OVERVIEW

Helvion Medical is a Swiss multinational medical technology company specialising in developing and manufacturing injection and infusion systems for self-medication, primarily in diabetes care and biotechnology [S1]. They manufacture all plastic components for their self-injection devices in-house, including tool design, manufacturing, injection moulding, and assembly [S2]. The company operates over 140 injection moulding machines and uses highly automated assembly processes for millions of injection pens and auto-injectors annually [S2]. As of 2025, Helvion Medical employs over 2,300 people and had an annual turnover of 612.4 million Swiss Francs [S1].

### KEY SIGNALS

#### EXPANSION & GROWTH

Helvion Medical is expanding its global manufacturing capacity with new facilities in the US [S4] and Germany [S3], commissioning new high-capacity lines [S5], and expanding tool manufacturing [S7].

**Implication:** This indicates a strong need for new or upgraded automation solutions for injection moulding and assembly to support increased production volumes.

#### PRODUCT DEMAND

Helvion Medical secured 11 new customer projects in Q1 FY 2026/27 <sup>[S5]</sup> and a record 37 new customer projects in FY 2025/26 <sup>[S6]</sup>, driven by strong demand for large-volume autoinjectors and biosimilar product launches <sup>[S5]</sup>.

**Implication:** The high demand and numerous new projects necessitate rapid scaling of production, creating an urgent need for efficient, high-volume automation.

#### TECHNOLOGY ADOPTION

Helvion Medical's new Leipzig II plant is establishing a digital foundation for future manufacturing, incorporating networked, scalable systems, MOM, and MES <sup>[S3]</sup>.

**Implication:** This suggests Helvion Medical is looking for advanced, integrated automation solutions that can connect with their digital manufacturing infrastructure, aligning with Brennwald Automation's potential for high-tech, turnkey lines.

#### RECOMMENDED CONTACT

Directly contact Daniel Brunner, COO and Deputy CEO <sup>[S8]</sup>. His role and background <sup>[S9]</sup> make him the ideal decision-maker for manufacturing automation investments.

#### SUGGESTED ANGLE

##### Scaling High-Volume Medical Device Production with Advanced Automation

Helvion Medical is rapidly expanding its manufacturing footprint globally <sup>[S3]</sup> to meet surging demand for large-volume autoinjectors and new customer projects <sup>[S5]</sup>. Brennwald Automation specialises in high-speed, high-cavity injection moulding automation and turnkey production lines for medical devices, directly addressing Helvion Medical's current strategic imperative to scale production efficiently and digitally.

#### OUTREACH SEQUENCE

Four emails, each with one ask and no links. Add your own greeting and signature, and check each draft reads true to you before it goes out.

**EMAIL 1, WHY YOU, WHY NOW**

**Subject: Production scaling**

In September 2026, Helvion Medical confirmed construction of its first US manufacturing facility in Greer, South Carolina, to expand production of self-injection systems. This expansion, alongside commissioning new high-capacity lines, often presents challenges in optimising new automation for high-volume output.

Brennwald Automation specialises in high-speed take-out systems for high-cavity moulds, downstream assembly, inspection, packaging, and turnkey production lines for medical devices. We could assist your new facilities in achieving optimal production for your plastic components.

Is scaling high-volume medical device production across your new facilities a key focus for you this year, or is there someone on your team I should speak to about this?

**EMAIL 2, PROOF AND A NEW ANGLE · DIAGNOSTIC CTA · DAY 3**

**Subject: Digital production**

Following up on your manufacturing expansion, I noted that in October 2026, Helvion Medical announced its new Leipzig II plant is establishing a digital foundation for future manufacturing. This includes networked, scalable systems, MOM, and MES.

Integrating high-performance automation into such a digital foundation from the start can reduce future operational complexities. It also helps accelerate time to market for the numerous new customer projects you secured in July 2026.

I put together a quick view of how integrating high-speed automation early could benefit your digital manufacturing foundations. Worth sending over?

**EMAIL 3, LOWER THE FRICTION · ROUTING CTA · DAY 6**

**Subject: Assembly automation**

I have sent a couple of emails regarding Helvion Medical's manufacturing expansion and automation needs. I understand you are busy, especially with the company manufacturing all plastic components for your self-injection devices in-house.

Given Helvion Medical operates over 140 injection moulding machines and is expanding tool manufacturing, optimising these processes for your high-volume disposables is likely a continuous effort.

Are you the right person overseeing the automation strategy for your injection moulding and assembly lines, or does someone else on your team own this programme?

EMAIL 4, VALUE FIRST BREAK-UP · PERMISSION TO CLOSE CTA · DAY 12

**Subject: Production capacity**

It seems my timing might be off for discussing advanced automation for your high-volume medical device production. I understand you have a lot on your plate with Helvion Medical's global manufacturing expansion.

If automation for the new lines is already decided, I will not keep writing.

Should I close the loop on this one, or is it a not yet?

**SOURCE LEDGER**

12 of 12 facts in this brief are linked to 9 source pages. The S numbers in the brief point here. A source page was found through Google and loaded when this brief was built; that does not mean every word of the claim was checked against the page.

**S1 · Helvion Medical - Wikipedia** [en.wikipedia.org](https://en.wikipedia.org)

Helvion Medical is a Swiss multinational medical technology company headquartered in Aarwil, Switzerland, specialising in developing and manufacturing injection and infusion systems for self-medication, primarily in diabetes care and biotechnology. COMPANY

As of 2025, Helvion Medical employs over 2,300 people and had an annual turnover of 612.4 million Swiss Francs. COMPANY · 2025

**S2 · Injection moulding | In-house precision moulding - Helvion Medical**

[helvionmedical.com](https://helvionmedical.com)

Helvion Medical manufactures all plastic components for its self-injection devices in-house, including tool design, manufacturing, injection moulding, and assembly. COMPANY

The company operates over 140 injection moulding machines and uses highly automated assembly processes for millions of injection pens and auto-injectors annually. COMPANY

**S3 · Building the digital factory - Helvion Medical** [helvionmedical.com](https://helvionmedical.com)

In October 2026, Helvion Medical announced that its new Leipzig II plant is establishing the digital foundation for future manufacturing, incorporating networked, scalable systems, Manufacturing Operations Management (MOM), and a Manufacturing Execution System (MES). TRIGGER · 2026-10

**S4 · Helvion Medical to build first US plant in South Carolina** [medtechmanufacturing.news](#)

In September 2026, Helvion Medical confirmed its first US manufacturing facility in Greer, South Carolina, which is under construction to expand the production of self-injection systems. TRIGGER · 2026-09

**S5 · Helvion Medical is off to a strong start in 2026/27** [helvionmedical.com](#)

In July 2026, Helvion Medical secured 11 new customer projects in the first quarter of fiscal year 2026/27, driven by strong demand for large-volume autoinjectors and biosimilar product launches. TRIGGER · 2026-07

In July 2026, Helvion Medical was commissioning its first high-capacity line for HelvioJect in Aarwil, and a new, fully automated high-bay warehouse in Leipzig was completed.

COMPANY · 2026-07

**S6 · Helvion Medical grows 18 % in core business and wins record number of customer projects** [helvionmedical.com](#)

In May 2026, Helvion Medical reported that its Delivery Systems segment revenue grew 18% to CHF 498.2 million in the financial year 2025/26 and won a record 37 new customer projects. TRIGGER · 2026-05

**S7 · Helvion Medical opens new tool manufacturing facility in Aarwil** [helvionmedical.com](#)

In April 2026, Helvion Medical opened a new tool manufacturing facility in Aarwil, expanding its capacity for designing and manufacturing plastic injection moulds for pens and autoinjectors for its global production facilities. COMPANY · 2026-04

**S8 · Management team | Helvion Medical** [helvionmedical.com](#)

Daniel Brunner has been the Chief Operating Officer (COO) since 2017 and also serves as Deputy CEO of Helvion Medical. CONTACT · 2017

**S9 · Daniel Brunner | Chief Operating Officer - Helvion Medical** [helvionmedical.com](#)

Daniel Brunner holds a B.S. in Mechanical Engineering and has prior experience in global operations and production management roles at other medical technology companies.

CONTACT